This is the authors' abstract. We don't add key points for this paper.
Introduction: Recombinant adeno-associated virus (rAAV)-mediated delivery of neutralizing antibodies is a promising strategy for rapid and durable prophylaxis against SARS-CoV-2. Methods: We evaluated the long-term expression, pharmacokinetics, immunogenicity, biodistribution, and protective efficacy of an rAAV vector of serotype DJ encoding the single-domain antibody P2C5 fused to a human Fc fragment (P2C5-Fc) in mice and common marmosets (Callithrix jacchus). Animals received a single intramuscular administration of rAAV-P2C5-Fc at a dose of 1 × 10¹³ vector genome copies per kg. Results: Rapid antibody detection in serum was observed, reaching peak concentrations (Cmax) by approximately 120 days and remaining at protective levels for >480 days in mice and up to 1,120 days in marmosets. Neutralizing titers closely paralleled serum P2C5-Fc concentrations and provided complete protection against lethal intranasal challenge with SARS-CoV-2 variants B.1.1.1 (Wuhan D614G) and BA.5 (Omicron) even at late time points (216 and 460 days post-administration in mice). Biodistribution analysis showed predominant localization of rAAV at the injection site and regional lymph nodes with minimal off-target spread. Moderate anti-AAV capsid antibody responses were detected, while anti-drug antibodies against P2C5-Fc remained undetectable in both species. Discussion: These findings demonstrate that a single intramuscular injection of rAAV-P2C5-Fc results in rapid onset, sustained expression, and long-term protective efficacy against SARS-CoV-2 variants in two preclinical models, supporting the potential of this platform for durable vectored immunoprophylaxis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ryabova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: